Vice President, Commercial Strategy
Peter Smith joined AnaptysBio in November 2018 with more than 30 years of experience in sales, marketing and program leadership in biopharma. Prior to joining AnaptysBio, Peter led the global marketing function for ozanimod in multiple sclerosis and inflammatory bowel disease at Receptos and then Celgene. Previously, he was vice president of the rare disease unit at Santarus, preparing for the commercialization of Ruconest®, for an ultra-orphan indication known as hereditary angioedema. Prior to Santarus, Peter held multiple roles of increasing responsibility at Biogen Idec, including Managing Director of the UK and Ireland affiliate where he was responsible for the launch of Tysabri®, and program leadership for Rituxan® in rheumatoid arthritis and other autoimmune indications. Peter has also held marketing and sales roles at ALZA, Roche and Syntex. Peter received his B.S. in Chemistry from Denison University.